<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938494</url>
  </required_header>
  <id_info>
    <org_study_id>V01-123A-201</org_study_id>
    <nct_id>NCT02938494</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream,&#xD;
      0.1%, in the Treatment of Acne Vulgaris&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the&#xD;
      Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream,&#xD;
      0.1%, in the Treatment of Acne Vulgaris&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12</measure>
    <time_frame>Baseline (Day 0), Week 12</time_frame>
    <description>Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment Success at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to &quot;Clear&quot; or &quot;Almost Clear&quot;. EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>IDP-123 Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tazorac Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-123 Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>IDP-123 Lotion</arm_group_label>
    <other_name>Lotion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazorac Cream</intervention_name>
    <description>Cream</description>
    <arm_group_label>Tazorac Cream</arm_group_label>
    <other_name>Tazorac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>Vehicle Lotion</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Cream</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at least 12 years of age and older.&#xD;
&#xD;
          -  Written and verbal informed consent must be obtained. Subjects less than age of&#xD;
             consent must sign an assent for the study and a parent or a legal guardian must sign&#xD;
             the informed consent (if subject reaches age of consent during the study they should&#xD;
             be re-consented at the next study visit).&#xD;
&#xD;
          -  Women of childbearing potential and females that are pre-menses must be willing to&#xD;
             practice effective contraception for the duration of the study. (Effective&#xD;
             contraception is defined as stabilized on oral contraceptive for at least 3 months,&#xD;
             IUD, condom with spermicidal, diaphragm with spermicidal, implant, Nuvaring,&#xD;
             injection, transdermal patch or abstinence.) Females on birth control pills must have&#xD;
             taken the same type pill for at least three months prior to entering the study and&#xD;
             must not change type during the study. Those who have used birth control pills in the&#xD;
             past must have discontinued usage at least three months prior to the start of the&#xD;
             study. Women who use birth control for acne control only should be excluded.&#xD;
&#xD;
          -  Pre-menses females and women of childbearing potential must have a negative urine&#xD;
             pregnancy test at the screening and baseline visits.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Use of an investigational drug or device within 30 days of enrollment or participation&#xD;
             in a research study concurrent with this study;&#xD;
&#xD;
          -  Any dermatological conditions on the face that could interfere with clinical&#xD;
             evaluations such as acne conglobata, acne fulminans, secondary acne, perioral&#xD;
             dermatitis, clinically significant rosacea, gramnegative folliculitis, dermatitis,&#xD;
             eczema.&#xD;
&#xD;
          -  Any underlying disease(s) or some other dermatological condition of the face that&#xD;
             requires the use of interfering topical or systemic therapy or makes evaluations and&#xD;
             lesion count inconclusive.&#xD;
&#xD;
          -  Subjects with a facial beard or mustache that could interfere with the study&#xD;
             assessments.&#xD;
&#xD;
          -  Evidence or history of cosmetic-related acne.&#xD;
&#xD;
          -  Subject has a history of experiencing significant burning or stinging when applying&#xD;
             any facial treatment (eg, make-up, soap, masks, washes, sunscreens, etc) to their&#xD;
             face.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 14</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 08</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 10</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 09</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 12</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 13</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 07</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 16</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 15</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 11</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <results_first_submitted>August 8, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <disposition_first_submitted>January 16, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 18, 2018</disposition_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IDP-123 Lotion</title>
          <description>Lotion&#xD;
IDP-123 Lotion: Lotion</description>
        </group>
        <group group_id="P2">
          <title>Tazorac Cream</title>
          <description>Cream&#xD;
Tazorac Cream: Cream</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Lotion</title>
          <description>Lotion&#xD;
Vehicle Lotion: Lotion</description>
        </group>
        <group group_id="P4">
          <title>Vehicle Cream</title>
          <description>Cream&#xD;
Vehicle Cream: Cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IDP-123 Lotion</title>
          <description>Lotion&#xD;
IDP-123 Lotion: Lotion</description>
        </group>
        <group group_id="B2">
          <title>Tazorac Cream</title>
          <description>Cream&#xD;
Tazorac Cream: Cream</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Lotion</title>
          <description>Lotion&#xD;
Vehicle Lotion: Lotion</description>
        </group>
        <group group_id="B4">
          <title>Vehicle Cream</title>
          <description>Cream&#xD;
Vehicle Cream: Cream</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" spread="10.2"/>
                    <measurement group_id="B2" value="22.0" spread="8.96"/>
                    <measurement group_id="B3" value="21.2" spread="9.27"/>
                    <measurement group_id="B4" value="21.2" spread="7.96"/>
                    <measurement group_id="B5" value="22.2" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12</title>
        <description>Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.</description>
        <time_frame>Baseline (Day 0), Week 12</time_frame>
        <population>Efficacy analyses compared IDP-123 Lotion and the combined Vehicle Lotion and Vehicle Cream groups, as pre-specified in the statistical analysis plan. There is no information for separate Vehicle Lotion and Vehicle Cream groups, since the comparator group was pre-specified to be combined Vehicle Lotion and Vehicle Cream.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-123 Lotion</title>
            <description>0.045% tazarotene</description>
          </group>
          <group group_id="O2">
            <title>Tazorac Cream</title>
            <description>Tazorac Cream 0.1%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Lotion and Vehicle Cream Combined</title>
            <description>Vehicle Lotion and Vehicle Cream Combined</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12</title>
          <description>Noninflammatory lesions were defined as follows: Open comedones (blackhead) - plugged hair follicle with dilated/open orifice, black in color; and Closed comedones (whitehead) - plugged hair follicle: small opening at skin surface. For noninflammatory facial lesions, open and closed comedones were recorded as a single count.</description>
          <population>Efficacy analyses compared IDP-123 Lotion and the combined Vehicle Lotion and Vehicle Cream groups, as pre-specified in the statistical analysis plan. There is no information for separate Vehicle Lotion and Vehicle Cream groups, since the comparator group was pre-specified to be combined Vehicle Lotion and Vehicle Cream.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.6" spread="13.98"/>
                    <measurement group_id="O2" value="-20.3" spread="13.67"/>
                    <measurement group_id="O3" value="-13.1" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12</title>
        <description>Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Efficacy analyses compared IDP-123 Lotion and the combined Vehicle Lotion and Vehicle Cream groups, as pre-specified in the statistical analysis plan. There is no information for separate Vehicle Lotion and Vehicle Cream groups, since the comparator group was pre-specified to be combined Vehicle Lotion and Vehicle Cream.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-123 Lotion</title>
            <description>0.045% tazarotene</description>
          </group>
          <group group_id="O2">
            <title>Tazorac Cream</title>
            <description>Tazorac Cream 0.1%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Lotion and Vehicle Cream Combined</title>
            <description>Vehicle Lotion and Vehicle Cream Combined</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12</title>
          <description>Inflammatory lesions were defined as follows: Papule - a solid, elevated lesion less than 5 millimeters (mm); and Pustule - an elevated lesion containing pus less than 5 mm. For inflammatory facial lesions, papules and pustules were recorded as a single count, while nodular lesions were counted and recorded separately.</description>
          <population>Efficacy analyses compared IDP-123 Lotion and the combined Vehicle Lotion and Vehicle Cream groups, as pre-specified in the statistical analysis plan. There is no information for separate Vehicle Lotion and Vehicle Cream groups, since the comparator group was pre-specified to be combined Vehicle Lotion and Vehicle Cream.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="8.99"/>
                    <measurement group_id="O2" value="-16.8" spread="10.96"/>
                    <measurement group_id="O3" value="-14.0" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment Success at Week 12</title>
        <description>Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to &quot;Clear&quot; or &quot;Almost Clear&quot;. EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Efficacy analyses compared IDP-123 Lotion and the combined Vehicle Lotion and Vehicle Cream groups, as pre-specified in the statistical analysis plan. There is no information for separate Vehicle Lotion and Vehicle Cream groups, since the comparator group was pre-specified to be combined Vehicle Lotion and Vehicle Cream.</population>
        <group_list>
          <group group_id="O1">
            <title>IDP-123 Lotion</title>
            <description>0.045% tazarotene</description>
          </group>
          <group group_id="O2">
            <title>Tazorac Cream</title>
            <description>Tazorac Cream 0.1%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Lotion and Vehicle Cream Combined</title>
            <description>Vehicle Lotion and Vehicle Cream Combined</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Success at Week 12</title>
          <description>Treatment success was defined as at least a 2-grade reduction from Baseline in EGSS score and an EGSS score equating to &quot;Clear&quot; or &quot;Almost Clear&quot;. EGSS was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
          <population>Efficacy analyses compared IDP-123 Lotion and the combined Vehicle Lotion and Vehicle Cream groups, as pre-specified in the statistical analysis plan. There is no information for separate Vehicle Lotion and Vehicle Cream groups, since the comparator group was pre-specified to be combined Vehicle Lotion and Vehicle Cream.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Randomized participants who used study drug at least once and provided ≥1 post-Baseline evaluation (Safety Population).</desc>
      <group_list>
        <group group_id="E1">
          <title>IDP-123 Lotion</title>
          <description>Lotion&#xD;
IDP-123 Lotion: Lotion</description>
        </group>
        <group group_id="E2">
          <title>Tazorac Cream</title>
          <description>Cream&#xD;
Tazorac Cream: Cream</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Lotion</title>
          <description>Lotion&#xD;
Vehicle Lotion: Lotion</description>
        </group>
        <group group_id="E4">
          <title>Vehicle Cream</title>
          <description>Cream&#xD;
Vehicle Cream: Cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>anya.loncaric@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

